Core Viewpoint - The company has demonstrated steady growth in its financial performance, with a focus on enhancing its core insurance business and adapting to market changes while maintaining a commitment to high-quality development [3][5][11]. Financial Performance - The company achieved a total revenue of RMB 200.50 billion, representing a year-on-year increase of 3.0% [6][11]. - The net profit attributable to shareholders reached RMB 27.89 billion, reflecting an 11.0% increase compared to the previous year [6][11]. - The operating profit was RMB 19.91 billion, up by 7.1% year-on-year [11]. - The group's embedded value increased to RMB 588.93 billion, a growth of 4.7% from the previous year [4][11]. Business Segments - The life insurance segment reported a new business value of RMB 9.54 billion, a significant increase of 32.3% year-on-year [4][11]. - The property insurance segment improved its combined ratio to 96.3%, down from 97.1%, indicating better underwriting performance [4][11]. - The company’s investment assets reached RMB 2.92 trillion, with a comprehensive investment return rate of 2.4%, a decrease of 0.6 percentage points from the previous year [4][11]. Strategic Focus - The company emphasizes a sustainable development approach, enhancing its governance structure and risk management systems to support long-term growth [5][6]. - The company is committed to innovation, focusing on integrating insurance products with health and wellness services, and advancing digital transformation initiatives [5][6]. - The company aims to expand its market presence through diversified channels and product offerings, particularly in health insurance and asset management [5][6]. Awards and Recognition - The company received multiple awards for its innovative financial services and commitment to consumer protection, highlighting its leadership in the insurance sector [6][7].

Core Viewpoint - China Pacific Insurance (Group) Co., Ltd. is committed to high-quality development, enhancing its comprehensive strength and market position while significantly improving service quality and effectiveness in supporting the real economy and people's well-being [2][3]. Financial Performance - The group's total operating revenue increased by 3.0%, with the operating profit attributable to shareholders rising by 7.1% and net profit increasing by 11.0% [3]. - The embedded value of the group grew by 4.7%, and total managed assets increased by 6.5% [3]. - The solvency ratios under the second phase of the solvency regulation remained sufficient, with the comprehensive solvency adequacy ratio increasing by 8 percentage points [4]. Business Segments Life Insurance - The life insurance segment saw a 13.1% increase in premium scale, with new business value rising by 32.3% [5]. - The agent workforce stabilized, with a 12.7% increase in core human productivity [5]. - The bancassurance channel's new business value surged by 156.1%, indicating strong growth in this distribution channel [5]. Property Insurance - The property insurance segment reported a 0.9% increase in gross premium income, with a notable improvement in underwriting profitability [6]. - The combined ratio for property insurance improved, reflecting better cost management and profitability [6]. Investment Management - The group maintained stable growth in managed assets, with a 6.5% increase in total managed assets [6]. - The investment performance showed resilience, with total investment income decreasing slightly by 2.1% year-on-year [8]. - The group is actively exploring new asset-liability matching management models to enhance investment performance [6]. Strategic Initiatives - The company is focusing on high-quality development, deepening reforms, and enhancing value creation capabilities through three main strategies: promoting health and wellness, internationalization, and integrating artificial intelligence [7]. - The company aims to strengthen its service capabilities and operational efficiency while building a leading insurance financial service group with market influence and international competitiveness [7].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 中國太平洋保險（集團）股份有限公司 CHINA PACIFIC INSURANCE (GROUP) CO., LTD. （於中華人民共和國註冊成立的股份有限公司） （股份代號：02601） 海外監管公告 本 公 告 乃 依 據《香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則》第13.10B條的披 露 義 務 而 作 出。 茲 載 列 該 公 告 如 下，僅 供 參 考。 承董事會命 中 國 太 平 洋 保 險（集 團）股 份 有 限 公 司 傅 帆 董事長 香 港，2025年8月29日 於 本 公 告 日 期，本 公 司 執 行 董 事 為 傅 帆 先 生 和 趙 永 剛 先 生；非 執 行 董 事 為 黃 迪 南 先 生、王 他 竽 先 生、陳 然 先 生、周 東 輝 先 生、路 巧 玲 女 士 和John Rob ...

Core Insights - The rapid implementation of DRG/DIP payment reform and the normalization of drug procurement have led to a surge in demand for "out-of-hospital medication coverage" among patients [1][10] - Insurance companies are accelerating the iteration and upgrade of high-end medical insurance products, with "out-of-purchase drug responsibility" becoming a focal point of this product upgrade [1][4] Group 1: Market Dynamics - The out-of-purchase drug responsibility allows insurance companies to reimburse patients for medications purchased outside the hospital when necessary drugs are unavailable [2][3] - Major insurance companies like ZhongAn, Pacific Health, and Xinhua Insurance are launching innovative products to meet the urgent demand for advanced medications and special medical services [2][4] Group 2: Policy Impact - The DRG/DIP payment model has pressured hospitals to control costs, leading to cautious use of high-value original and imported drugs, pushing patients towards external purchasing channels [3][10] - The National Healthcare Security Administration has introduced measures to control unreasonable medical expenses, which has further influenced patient medication channels and cost-sharing models [2][7] Group 3: Product Innovation - Recent insurance products have incorporated out-of-purchase drug responsibilities, with companies like ZhongAn and Pacific Health offering comprehensive coverage without restrictions on disease types or medication lists [4][5] - Xinhua Insurance has made bold attempts in out-of-purchase drug responsibility, including a wide range of medications and specialized health management services [6][9] Group 4: Future Outlook - The collaboration between commercial insurance and basic medical insurance is crucial for developing a new payment ecosystem for innovative drugs [7][10] - The introduction of the "three exclusions" policy is expected to enhance the role of commercial insurance in covering high-value innovative drugs, providing a clearer boundary for insurance responsibilities [8][9]